[유한 100주년]⑤ '황금알 낳는 거위' 렉라자, 로열티 수혜

Yuhan Corporation is successfully transitioning its business model from generics to high-margin technology royalties through the global expansion of Leclaza. While initial market penetration in the US and Europe is slower than expected, the upcoming overall survival (OS) data from clinical trials will be the decisive factor for its long-term commercial competitiveness against Tagrisso.